Organic solvent nanofiltration: A platform for removal of genotoxins from active pharmaceutical ingredients

Journal of Membrane Science

Volumn 381, Issue 1-2, 2011, Pages 21-33

  Székely, György ^a,b   Bandarra, Joao ^a   Heggie, William ^a   Sellergren, Börje ^b   Ferreira, Frederico Castelo ^c  

^a Hovione FarmaCiencia SA   (Portugal)

^b TU DORTMUND UNIVERSITY   (Germany)

^c INSTITUTO SUPERIOR TÉCNICO   (Portugal)

Author keywords

Active pharmaceutical ingredient; Genotoxic impurities; Organic solvent nanofiltration; Purification

Indexed keywords

ACTIVE PHARMACEUTICAL INGREDIENTS; APPLIED PRESSURE; COMPOUND STRUCTURES; CONTAMINATION LEVELS; DIAFILTRATION; ECONOMIC IMPACTS; GENOTOXIC IMPURITIES; GENOTOXINS; HIGH LOAD; LITERATURE DATA; MEMBRANE REJECTION; METHYL ETHYL KETONES; MODEL COMPOUND; MOLECULAR SIZE; ORGANIC SOLVENT NANOFILTRATION; PHARMACEUTICAL INDUSTRY; POLAR SOLVENTS; POST REACTION; TETRAHYDROFURANS; THRESHOLD LIMITS;

DISSOLUTION; KETONES; MEMBRANES; NANOFILTRATION; ORGANIC COMPOUNDS; ORGANIC SOLVENTS; PURIFICATION; SOLVENTS;

REMOVAL;

2 BUTANONE; ACTIVE PHARMACEUTICAL INGREDIENT; AMIDE; CHEMICAL COMPOUND; GENOTOXIC IMPURITY; MACROLIDE; ORGANIC SOLVENT; STEROID; SULFUR ACID DERIVATIVE; TETRAHYDROFURAN; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ARTICLE; CHEMICAL REACTION; CHEMICAL STRUCTURE; DIAFILTRATION; DISSOLUTION; DRUG IMPURITY; DRUG INDUSTRY; GENOTOXICITY; MAXIMUM ALLOWABLE CONCENTRATION; MOLECULAR SIZE; MOLECULAR WEIGHT; NANOFILTRATION; ORGANIC SOLVENT NANOFILTRATION; PRIORITY JOURNAL; PURIFICATION; SOLUBILITY;

EID: 80052037310     PISSN: 03767388     EISSN: 18733123     Source Type: Journal    
DOI: 10.1016/j.memsci.2011.07.007     Document Type: Article

References (44)

1. Robinson D.I. Control of genotoxic impurities in active pharmaceutical ingredients: a review and perspective. Org. Process Res. Dev. 2010, 14:946-959.
2. Guidance for industry, Genotoxic and carcinogenic impurities in drug substances and products: recommended approaches, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), December 2008.
3. Rogawski M.A. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res. 2006, 69:273-294.
4. http://www.drugbank.ca/.
5. http://www.pubchem.com/.
6. Czock D., Keller F., Rasche F.M., Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin. Pharmacokinet. 2005, 44:61-98.
7. Martindale The Extra Pharmacopoeia 1993, 724. 30th ed. J.E.F. Reynolds (Ed.).
8. Crim C., Pierre L.N., Daley-Yates P.D. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin. Therapeut. 2001, 23:1339-1354.
9. Zhang K., Wu E., Patick A. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob. Agents Chemother. 2001, 45:1086-1093.
10. Press release, European Medicines Agency, doc.ref.: EMEA/CHMP/492059/2007.
11. Gerber C., Toelle H.G. What happened: The chemistry side of the incident with EMS contamination in Viracept tablets. Toxicol. Lett. 2009, 190:248-253.
12. De Castro K.A., Ko J., Park D., Park S., Rhee H. Reduction of ethyl benzoylacetate and selective protection of 2-(3-hydroxy-1-phenylpropyl)-4-methylphenol: a new and facile synthesis of Tolterodine. Org. Process Res. Dev. 2007, 11:918-921.
13. Brown A.D., Davis R.D., Fitzgerald R.N., Glover B.N., Harvey K.A., Jones L.A., Liu B., Patterson D.E., Sharp M.J. Process development for Sodelglitazar. Org. Process Res. Dev. 2009, 13:297-302.
14. Garte S.J., Hood A.T., Hochwalt A.E., Eustachio P., Snyder C.A., Segal A., Albert R.E. Carcinogen specificity in the activation of transforming genes by direct-acting alkylating agents. Carcinogenesis 1985, 12:1709-1712.
15. Final report of the safety assessment of urea. Int. J. Toxicol. 2005, 24:1-56.
16. Izdebski J., Pelka J. Peptide synthesis using disubstituted carbodiimides which form dichloromethane-soluble urea derivatives. Peptides, Proceedings of the 18th European Peptide Symposium 1984, 113-116.
17. Kozekov I.D., Turesky R.J., Alas G.R., Harris C.M., Harris T.M., Rizzo C.J. Formation of deoxyguanosine cross-links from calf thymus DNA treated with acrolein and 4-hydroxy-2-nonenal. Chem. Res. Toxicol. 2010, 23:1701-1713.
18. Müller L., Mauthe R.J., Riley C.M., Andino M.M., Antonis D., Beels C., DeGeorge J., Knaep A.G.M., Ellison D., Fagerland J.A., Frank R., Fritschel B., Galloway S., Harpur E., Humfrey C.D.N., Jacks A.S., Jagota N. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. Regul. Toxicol. Pharm. 2006, 44:198-211.
19. Maddula S.R., Kharkar M., Manudhane K., Kale S., Bhori A., Lali A., Dubey P.K., Sarma J.K.R., Bhattacharya A., Bandichhor R. Preparative chromatography technique in the removal of isostructural genotoxic impurity in Rizatriptan: use of physicochemical descriptors of solute and adsorbent. Org. Process Res. Dev. 2009, 13:683-689.
20. Lee C., Helmy R., Strulson C., Plewa J., Kolodziej E., Antonucci V., Mao B., Welch C.J., Ge Z., Al-Sayah M.A. Removal of electrophilic potential genotoxic impurities using nucleophilic reactive resins. Org. Process Res. Dev. 2010, 14:1021-1026.
21. Yang Y., Tjia R. Process modeling and optimization of batch fractional distillation to increase throughput and yield in manufacture of active pharmaceutical ingredient. Comput. Chem. Eng. 2010, 34:1030-1035.
22. Ferreira F.C., Macedo H., Cocchini U., Livingston A.G. Development of a liquid-phase process for recycling resolving agents within diastereomeric resolutions. Org. Process Res. Dev. 2006, 10:784-793.
23. White L.S. Development of large-scale applications in organic solvent nanofiltration and pervaporation for chemical and refining processes. J. Membr. Sci. 2006, 286:26-35.
24. Vandezande P., Gevers L.E.M., Vankelecom I.F.J. Solvent resistant nanofiltration: separating on a molecular level. Chem. Soc. Rev. 2008, 37:365-405.
25. Pink C.J., Wong H.T., Ferreira F.C., Livingston A.G. Organic solvent nanofiltration and adsorbents, a hybrid approach to achieve ultra low palladium contamination of post coupling reaction products. Org. Process Res. Dev. 2008, 12:589-595.
26. Geens J., De Witte B., Van der Bruggen B. Removal of API's (active pharmaceutical ingredients) from organic solvents by nanofiltration. Sep. Sci. Technol. 2007, 42(11):2435-2449.
27. Ghazali N.F., Ferreira F.C., White A.J.P., Livingston A.G. Enantiomer separation by enantioselective inclusion complexation-organic solvent nanofiltration. Tetrahedron: Asymmetry 2006, 17:1846-1852.
28. Ferreira F.C., Branco L.C., Verma K.K., Crespo J.G., Afonso C.A.M. Application of nanofiltration for re-use of Sharpless catalytic system in asymmetric di-hydroxylation. Tetrahedron: Asymmetry 2007, 18:1637-1641.
29. Aerts S., Weyten H., Buekenhoudt A., Gevers L.E.M., Vankelecom I.F.J., Jacobs P. Recycling of the homogeneous co-Jacobsen catalyst through solvent-resistant nanofiltration. Chem. Commun. 2004, 6:710-711.
30. Cano-Odena A., Vandezande P., Fournier D., Van Camp W., Du Prez F.E., Vankelecom I.F.J. Solvent-resistant nanofiltration for product purification and catalyst recovery in click chemistry reactions. Chem. Eur. J. 2010, 16:1061-1067.
31. Haerens K., Van Deuren S., Matthijs E., Van der Bruggen B. Challenges for recycling ionic liquids by using pressure driven membrane processes. Green Chem. 2010, 12:2182-2188.
32. Lin J.C.T., Livingston A.G. Nanofiltration membrane cascade for continuous solvent exchange. Chem. Eng. Sci. 2007, 62:2728-2736.
33. Sheth J.P., Qin Y.J., Sirkar K.K., Baltzis B.C. Nanofiltration-based diafiltration process for solvent exchange in pharmaceutical manufacturing. J. Membr. Sci. 2003, 211:251-261.
34. Valadez-Blanco R., Ferreira F.C., Jorge R.F., Livingston A.G. A membrane bioreactor for biotransformations of hydrophobic molecules using organic solvent nanofiltration membranes. J. Membr. Sci. 2008, 317:50-64.
35. Santos J.L.C., Hidalgo A., Oliveira R., Crespo J.G. Analysis of solvent flux through nanofiltration membranes by mechanistic, chemometric and hybrid modelling. J. Membr. Sci. 2007, 300:191-204.
36. Geens J., Hillen A., Bettens B., Van der Bruggen B., Vandecasteele C. Solute transport in non-aqueous nanofiltration: effect of membrane material. J. Chem. Technol. Biotechnol. 2005, 80:1371-1377.
37. Darvishmanesh S., Buekenhoudt A., Degrève J., Van der Bruggen B. Coupled series-parallel resistance model for transport of solvent through inorganic nanofiltration membranes. Sep. Purif. Technol. 2009, 70:46-52.
38. Cuperus P. Recovery of organic solvents and valuable components by membrane separation. Chem. Ing. Tech. 2005, 77:1000-1001.
39. http://achema-content2.dechema.de/achema2009_media/Downloads/Presse/08_09Nanofiltration.pdf.
40. Phenomenex International Catalogue (2010/2011) 387.
41. Mulder M. Basic Principles of Membrane Technology 1996, Kluwer Academic Publishers, Dordrecht, The Netherlands.
42. A. Kleemann, J. Engel, B. Kutscher, D. Reichert, Pharmaceutical substances: syntheses, patents, applications, Thieme, 3rd ed., 1999, p. 210.
43. Dermatologic Disease Database. http://www.aocd.org/skin/dermatologic_diseases/steroids.html.
44. EMEA guidelines " Limits for Genotoxic Impurities" EMEA/CHMP/QWP/251334/2006.